No takes yet. Share an insight, caveat, or question.
In vitro and in vivo study demonstrates that LINC01132 knockdown suppresses epithelial ovarian cancer progression via miR-431-5p and SOX9, suggesting a novel therapeutic target.
Zhu et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: